According to TechSci Research report, “India Liver Cancer Therapeutics Market – By Region, Competition, Forecast, and Opportunities, 2029”, the India liver cancer therapeutics market is anticipated to grow at an impressive rate during the forecast period. This can be ascribed due to the increasing use of anabolic steroids. Anabolic steroids are masculine hormones used by certain athletes to increase their strength and muscle mass. Prolonged use of anabolic steroids may slightly increase the risk of hepatocellular cancer. The misuse of anabolic steroids has been linked to several liver-related health problems, including liver damage, liver cancer, and other liver-related diseases. Anabolic steroids are synthetic substances that mimic the effects of testosterone in the body. They are often used by athletes and bodybuilders to increase muscle mass, strength, and performance. However, the misuse of anabolic steroids can lead to serious health problems, including liver damage. Anabolic steroids are metabolized by the liver, and prolonged use can lead to liver damage, including liver tumors and liver cancer. Such factors will drive the growth of the India liver cancer therapeutics market during the forecast period.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “India Liver Cancer Therapeutics Market” – https://www.techsciresearch.com/report/india-liver-cancer-therapeutics-market/15610.html
Major trend which is there in the India liver cancer therapeutics market is collaborations and partnerships. As the market becomes increasingly competitive and complex, companies are looking for ways to collaborate and leverage each other’s strength to drive innovation and growth. Collaborations and partnerships can take many forms, such as joint ventures, licensing agreements, research collaborations, and co-marketing arrangements. For example, pharmaceutical companies may collaborate with academic institutions or biotech startups to develop new drugs or therapies for liver cancer. They may also partner with diagnostic companies or imaging providers to improve early detection and monitoring of liver cancer. Collaborations and partnerships can help companies gain access to new markets or distribution channels. For example, a company may partner with a local distributor or healthcare provider to expand its reach in a specific geographic region.
Challenge which is being faced by the India liver cancer therapeutics market is lack of trained professionals, the diagnosis and treatment of liver cancer require specialized knowledge and skills, and there is a shortage of healthcare professionals with expertise in this area. This shortage can lead to delays in diagnosis, incorrect treatment decisions, and inadequate patient care. Additionally, the limited availability of trained healthcare professionals can make it difficult to provide quality care to patients in remote or underserved areas. Efforts are being made to address this challenge by increasing the number of training programs and specialized courses for healthcare professionals in the field of liver cancer diagnosis and treatment.
The India liver cancer therapeutics market can be segmented by cancer type, therapy, route of administration, distribution channel, and region. Based on route of administration, the market can be segmented into oral, intravenous, and others. Oral route of administration is one of the common routes used in India for liver cancer therapeutics. It involves the use of drugs in the form of tablets or capsules that are swallowed and absorbed in the gastrointestinal tract. Oral administration offers several advantages, including ease of use, patient compliance, and convenient dosing schedules. It is also a non-invasive method, which means that it does not require injections or other invasive procedures. Some liver cancer drugs available in India are administered orally, including sorafenib, regorafenib, and lenvatinib. However, the choice of the route of administration depends on various factors, such as the drug’s pharmacokinetic properties, the patient’s condition, and the treatment goals. In some cases, other routes of administration such as intravenous, intramuscular, or subcutaneous may be preferred over oral administration.
Based on the distribution channel, the India liver cancer therapeutics market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies play an important role in the distribution of liver cancer therapeutics in India. These pharmacies are usually located in local communities and provide access to medication for patients with liver cancer who may not have easy access to hospital pharmacies. Retail pharmacies can also provide advice and counselling to patients regarding their medications and help to ensure adherence to treatment regimens. The growth of retail pharmacy chains in India has helped to increase access to liver cancer therapeutics in smaller towns and rural areas.
Major companies operating in the India liver cancer therapeutics market are:
- Natco Pharma Ltd.
- Reddy’s Laboratories Ltd.
- Intas Pharmaceuticals Ltd.
- Mylan Pharmaceuticals Pvt. Ltd.
- Lupin Ltd., Biocon Ltd.
- Hetero Labs Ltd
In 2021, Zydus Cadila Healthcare Ltd. launched a generic version of Regorafenib, a targeted therapy drug used in the treatment of liver cancer.
In 2021, Dr. Reddy’s Laboratories Ltd. announced that it had received approval from the DCGI to conduct Phase III clinical trials of Sputnik V vaccine in India.
In 2019, Natco Pharma Ltd. received approval from the Drug Controller General of India (DCGI) for its generic version of sorafenib tosylate.
In 2016, Hetero Labs Ltd. launched its generic version of sorafenib tosylate, under the brand name SORAFENAT, for the treatment of liver cancer.
Customers can also request for 10% free customization on this report.
“The India liver cancer therapeutics market is expected to grow during the forecast period due to the rising demand for early diagnosis with medical benefits along with the growing preference for laparoscopic and robotic surgeries across the region. During the early stage of liver cancer, the cancer is localized and has not propagated anywhere else in the body. Therefore, to avoid further growth and spread of liver cancer, the cancerous liver cells should be removed surgically. Besides, increasing concern about healthy lifestyles and growing expenditure on health and wellness are further expected to create lucrative opportunities for the growth of the market” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.
“India Liver Cancer Therapeutics Market,By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, and Liver Metastasis), By Therapy (Targeted Therapy, Chemotherapy and Radiation Therapy, Immunotherapy, and Others), By Route of Administration (Oral, Intravenous, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region, Competition, Forecast, and Opportunities, 2029” has evaluated the future growth potential of the India liver cancer therapeutics market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the India liver cancer therapeutics market.
Download Free Sample Report – https://www.techsciresearch.com/sample-report.aspx?cid=15610
About TechSci Research:
TechSci Research is a research-based management consulting firm providing market research and advisory solutions to its customers worldwide, spanning a range of industries. TechSci Research’s core values are value, integrity and insight. Led by a team of dynamic industry experts, TechSci Research provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, TechSci’s client leads rather than follow market trends. Not bound by legacy, TechSci’s cutting-edge research model leverages its decades of research knowledge and increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, TechSci Research reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com
